GUPEA >
Sahlgrenska Academy / Sahlgrenska akademin >
Institute of Clinical Sciences / Institutionen för kliniska vetenskaper >
Doctoral Theses / Doktorsavhandlingar Institutionen för kliniska vetenskaper >

Methotrexate and Risk of Cutaneous Melanoma


Please use this identifier to cite or link to this item: http://hdl.handle.net/2077/60781

Files in This Item:

File Description SizeFormat
gupea_2077_60781_1.pdfCover11698KbAdobe PDF
View/Open
gupea_2077_60781_2.pdfAbstract113KbAdobe PDF
View/Open
gupea_2077_60781_3.pdfThesis frame2968KbAdobe PDF
View/Open
Title: Methotrexate and Risk of Cutaneous Melanoma
Authors: Polesie, Sam
E-mail: sam.polesie@vgregion.se
Issue Date: 6-Sep-2019
University: University of Gothenburg. Sahlgrenska Academy
Institution: Institute of Clinical Sciences. Department of Dermatology and Venereology
Parts of work: I Polesie S, Gillstedt M, Sönnergren HH, Osmancevic A, Paoli J. Methotrexate treatment and risk for cutaneous malignant melanoma: a retrospective comparative registry-based cohort study. Br J Dermatol. 2017 Jun;176(6):1492-1499.
VIEW ARTICLE


II Polesie S, Gillstedt M, Paoli J, Osmancevic A. Methotrexate Exposure and Risk of Cutaneous Malignant Melanoma: No Evidence of a Dose-response Relationship. Acta Derm Venereol. 2018 Oct 10;98(9):888-895.
VIEW ARTICLE


III Polesie S, Gillstedt M, Paoli J, Osmancevic A. Methotrexate and melanoma-specific mortality. J Eur Acad Dermatol Venereol. 2019 Mar; 33(3):e123-e125 Oct 25.
VIEW ARTICLE


IV Polesie S, Gillstedt M, Paoli J, Osmancevic A. Methotrexate treatment in patients with a history of cutaneous melanoma and the risk of a consecutive primary melanoma: A national retrospective registry-based cohort study. J Am Acad Dermatol. 2017 Jul;77(1):161-163
VIEW ARTICLE


V Polesie S, Gillstedt M, Paoli J, Osmancevic A. Methotrexate treatment for psoriasis patients and risk of cutaneous melanoma: a nested case-control study. In manuscript (submitted)

VI Polesie S, Gillstedt M, Zaar O, Osmancevic A, Paoli J. Dermoscopic Features of Melanomas in Organ Transplant Recipients. Acta Derm Venereol. 2019 Jul 12. [Epub ahead of print].
VIEW ARTICLE

Date of Defence: 2019-12-05
Disputation: Torsdagen den 5 december 2019, kl. 09.00, hudklinikens föreläsningssal, Gröna stråket 16, Sahlgrenska universitetssjukhus/Sahlgrenska, Göteborg
Degree: Doctor of Philosophy (Medicine)
Publication type: Doctoral thesis
Keywords: methotrexate
cutaneous melanoma
risk
organ transplant recipients
dermoscopy
Abstract: Methotrexate (MTX) is an anti-inflammatory and immunosuppressive drug commonly used to treat psoriasis, psoriatic arthritis and rheumatoid arthritis. Cutaneous malignant melanoma (CMM) is a common and dangerous type of skin cancer and in recent decades a noteworthy increase in incidence has been observed. In Sweden, CMM is the fifth most common form of cancer in both men and women. This type of cancer is more frequent among patients with an impaired immune system such as organ transp... more
ISBN: 978-91-7833-454-4 (PRINT)
978-91-7833-455-1 (PDF)
URI: http://hdl.handle.net/2077/60781
Appears in Collections:Doctoral Theses from Sahlgrenska Academy
Doctoral Theses from University of Gothenburg / Doktorsavhandlingar från Göteborgs universitet
Doctoral Theses / Doktorsavhandlingar Institutionen för kliniska vetenskaper

 

 

© Göteborgs universitet 2011